

## DAFTAR PUSTAKA

1. Chopade TR, Bollu PC. Hemifacial Spasm [Internet]. StatPearls. 2023. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2241620>
2. Tambasco N, Filidei M, Nigro P, Parnetti L, Simoni S. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies. *Toxins* (Basel). 2021 Dec 9;13(12):881.
3. Duarte GS, Rodrigues FB, Castelão M, Marques RE, Ferreira J, Sampaio C, et al. Botulinum toxin type A therapy for hemifacial spasm. *Cochrane Database of Systematic Reviews*. 2020 Nov 19;2020(11).
4. Park CK, Lim SH, Park K. Clinical Application of Botulinum Toxin for Hemifacial Spasm. *Life*. 2023 Aug 17;13(8):1760.
5. Fadlah NN, Marbun P. Mampu Atasi Kerutan pada Wajah, Kenali Lebih Dalam Suntik Botox di Sini. <https://www.gooddoctor.co.id/hidup-sehat/kulit/suntik-botox/>. 2020.
6. UMP DKI Jakarta 2024 Diumumkan Hari Ini, Ini Rumus Perhitungannya. <https://jakarta.bpk.go.id/ump-dki-jakarta-2024-diumumkan-hari-ini-ini-rumus-perhitungannya/>. 2023.
7. World Bank Country and Lending Groups. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. 2023.
8. Pape UJ, Ali R. Indonesia Poverty Assessment - Pathways towards Economic Security [Internet]. Washington; 2023 May [cited 2023 Oct 31]. Available from: <http://documents.worldbank.org/curated/en/099041923101015385/P17567409bd69f01809b940840b40608e56>
9. Dou NN, Zhong J, Zhou QM, Zhu J, Wang YN, Xia L, et al. The mechanism of hemifacial spasm: a new understanding of the offending artery. *Neurol Res*. 2015 Feb 18;37(2):184–8.
10. Park K, Park JS, editors. *Hemifacial Spasm*. Singapore: Springer Singapore; 2020.

11. Liu J, Yuan Y, Fang Y, Zhang L, Xu XL, Liu HJ, et al. Microvascular decompression for atypical hemifacial spasm: lessons learned from a retrospective study of 12 cases. *J Neurosurg*. 2016 Feb;124(2):397–402.
12. Ozzello DJ, Giacometti JN. Botulinum Toxins for Treating Essential Blepharospasm and Hemifacial Spasm. *Int Ophthalmol Clin*. 2018;58(1):49–61.
13. Chaudhry N, Srivastava A, Joshi L. Hemifacial spasm: The past, present and future. *J Neurol Sci*. 2015 Sep;356(1–2):27–31.
14. Nurminen P, Marjamaa J, Niemelä M, Sairanen T. Incidence and prevalence of Hemifacial Spasm in Finland’s largest hospital district. *J Neurol Sci*. 2023 Mar;446:120587.
15. Lu AY, Yeung JT, Gerrard JL, Michaelides EM, Sekula RF, Bulsara KR. Hemifacial spasm and neurovascular compression. *ScientificWorldJournal*. 2014;2014:349319.
16. Lefaucheur JP. New insights into the pathophysiology of primary hemifacial spasm. *Neurochirurgie*. 2018 May;64(2):87–93.
17. Choi SI, Kim MW, Park DY, Huh R, Jang DH. Electrophysiologic investigation during facial motor neuron suppression in patients with hemifacial spasm: possible pathophysiology of hemifacial spasm: a pilot study. *Ann Rehabil Med*. 2013 Dec;37(6):839–47.
18. da Silva Martins WC, de Albuquerque LAF, de Carvalho GTC, Dourado JC, Dellaretti M, de Sousa AA. Tenth case of bilateral hemifacial spasm treated by microvascular decompression: Review of the pathophysiology. *Surg Neurol Int*. 2017;8:225.
19. Blitzer AL, Phelps PO. Facial spasms. *Disease-a-Month*. 2020 Oct;66(10):101041.
20. Lefaucheur JP, Ben Daamer N, Sangla S, Le Guerinel C. Diagnosis of primary hemifacial spasm. *Neurochirurgie*. 2018 May;64(2):82–6.
21. Yan X, Ma C, Gu J, Qu J, Quan J, Zhang X, et al. Facial root entry/exit zone contact in microvascular decompression for hemifacial spasm: a historical control study. *Ann Transl Med*. 2021 May;9(10):834.

22. Ghali MGZ, Srinivasan VM, Viswanathan A. Microvascular Decompression for Hemifacial Spasm. *Int Ophthalmol Clin*. 2018;58(1):111–21.
23. Sindou M, Mercier P. Microvascular decompression for hemifacial spasm : Surgical techniques and intraoperative monitoring. *Neurochirurgie*. 2018 May;64(2):133–43.
24. Maan JS, Duong T vi H, Saadabadi A. Carbamazepine. 2023.
25. Yasaei R, Katta S, Saadabadi A. Gabapentin. 2023.
26. Basit H, Kahwaji CI. Clonazepam. 2023.
27. Ghanavatian S, Derian A. Baclofen. 2023.
28. Wabbels B, Yaqubi A. Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters. *J Neural Transm (Vienna)*. 2021 Jun;128(6):793–802.
29. Blitzer A, Benson BE, Kirke DN. Botulinum Neurotoxin for Head and Neck Disorders [Internet]. Second Edition. Blitzer A, Benson BE, Kirke DN, editors. Stuttgart: Georg Thieme Verlag; 2020. Available from: <http://www.thieme-connect.de/DOI/DOI?10.1055/b-006-161172>
30. Alter KE, Wilson NA. Botulinum Neurotoxin Injection Manual. 1st edition. Demos Medical; 2014.
31. Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. *Toxins (Basel)*. 2021 Jan 14;13(1).
32. Whitcup SM, Hallett M, editors. Botulinum Toxin Therapy. Vol. 263. Cham: Springer International Publishing; 2021.
33. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. *Pharmacol Rev*. 2017 Apr;69(2):200–35.
34. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. *J Clin Aesthet Dermatol*. 2014 Feb;7(2):31–9.
35. Tian R, Widel M, Imanian B. The Light Chain Domain and Especially the C-Terminus of Receptor-Binding Domain of the Botulinum Neurotoxin

- (BoNT) Are the Hotspots for Amino Acid Variability and Toxin Type Diversity. *Genes (Basel)*. 2022 Oct 21;13(10):1915.
36. Rossetto O, Montecucco C. Tetanus and Botulinum Neurotoxins. In: *Microbial Toxins*. Springer, Dordrecht; 2018. p. 171–86.
  37. Rummel A, Binz T, editors. *Botulinum Neurotoxins*. Vol. 364. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013.
  38. Tighe AP, Schiavo G. Botulinum neurotoxins: Mechanism of action. *Toxicon*. 2013 Jun;67:87–93.
  39. Pantano S, Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. *Cellular and Molecular Life Sciences*. 2014 Mar 11;71(5):793–811.
  40. Jankovic J. Botulinum toxin: State of the art. *Movement Disorders*. 2017 Aug 22;32(8):1131–8.
  41. Jabbari B, editor. *Botulinum Toxin Treatment in Clinical Medicine*. Cham: Springer International Publishing; 2018.
  42. Kim DW, Lee SK, Ahnn J. Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception. *Toxins (Basel)*. 2015 Jun 30;7(7):2435–53.
  43. Skryabina AA, Golenok ES, Sobkh MM, Nikiforov V V. Structure and mechanism of action of botulinum and tetanus neurotoxins: A review. *Epidemiology and Infectious Diseases*. 2023 Jun 1;28(2):118–27.
  44. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. *Nat Rev Microbiol*. 2014 Aug 30;12(8):535–49.
  45. Rossetto O, Montecucco C. Molecular Mechanisms of Botulinum Toxin. In: *Treatment of Dystonia*. Cambridge University Press; 2018. p. 102–5.
  46. Dong M, Masuyer G, Stenmark P. Botulinum and Tetanus Neurotoxins. *Annu Rev Biochem*. 2019 Jun 20;88(1):811–37.
  47. Pirazzini M, Azarnia Tehran D, Zanetti G, Rossetto O, Montecucco C. Hsp90 and Thioredoxin-Thioredoxin Reductase enable the catalytic activity of Clostridial neurotoxins inside nerve terminals. *Toxicon*. 2018 Jun;147:32–7.

48. Rossetto O, Megighian A, Scorzeto M, Montecucco C. Botulinum neurotoxins. *Toxicon*. 2013 Jun;67:31–6.
49. Kumar R, Dhaliwal H, Kukreja R, Singh B. The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems. *Semin Neurol*. 2016 Feb 11;36(01):010–9.
50. Wheeler A, Smith HS. Botulinum toxins: Mechanisms of action, antinociception and clinical applications. *Toxicology*. 2013 Apr;306:124–46.
51. Padda IS, Tadi P. *Botulinum Toxin*. 2023.
52. Foster KA, editor. *Clinical Applications of Botulinum Neurotoxin*. New York, NY: Springer New York; 2014.
53. Witmanowski H, Błochowiak K. The whole truth about botulinum toxin - a review. *Postepy Dermatol Alergol*. 2020 Dec;37(6):853–61.
54. Lolekha P, Choolam A, Kulkantrakorn K. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. *Neurological Sciences*. 2017 Nov 7;38(11):2031–6.
55. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. *Clin Exp Ophthalmol*. 2014 Apr 4;42(3):254–61.
56. Teekaput C, Teekaput K, Thiankhaw K. Preseptal and Pretarsal Botulinum Toxin Injection in Hemifacial Spasm and Blepharospasm: A 10-Year Comparative Study. *Ther Clin Risk Manag*. 2023;19:35–42.
57. Cohen DA, Savino PJ, Stern MB, Hurtig HI. Botulinum Injection Therapy for Blepharospasm. *Clin Neuropharmacol*. 1986 Oct;9(5):415–29.
58. Li YJ, Huang Y, Ding Q, Gu ZH, Pan XL. Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial. *Genet Mol Res*. 2015 Feb 6;14(1):1136–44.
59. Lee JA, Jo KW, Kong DS, Park K. Using the New Clinical Grading Scale for Quantification of the Severity of Hemifacial Spasm: Correlations with a Quality of Life Scale. *Stereotact Funct Neurosurg*. 2012;90(1):16–9.

60. Rojanapitayakorn P. การศึกษาเปรียบเทียบประสิทธิผลการรักษาโรคใบหน้ากระตุกครึ่งซีกของยาโบ툴ินัมที่ออกซิเจนขนาดยาปกติกับขนาดยา 75% ของขนาดปกติที่โรงพยาบาลพระมงกุฎเกล้า. Hemifacial spasm: comparative study efficacy of treatment with 75% dose and normal dose botulinum toxin injection. 2019.
61. Ledda C, Artusi CA, Tribolo A, Rinaldi D, Imbalzano G, Lopiano L, et al. Time to onset and duration of botulinum toxin efficacy in movement disorders. *J Neurol*. 2022 Jul 3;269(7):3706–12.
62. Auger RG, Whisnant JP. Hemifacial Spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. *Arch Neurol*. 1990 Nov 1;47(11):1233–4.
63. Nilsen B, Le KD, Dietrichs E. Prevalence of hemifacial spasm in Oslo, Norway. *Neurology*. 2004 Oct 26;63(8):1532–3.
64. Poonyathalang A, Preechawat P, Jamnansiri U. Low-Dose Botulinum Toxin A for Treatment of Blepharospasm and Hemifacial Spasm. *Jpn J Ophthalmol*. 2005 Aug 1;49(4):327–8.
65. Suputtitada A, Phanthumchinda K, Lochareernkul C, Suwanwela NC. Hemifacial spasm: results of treatment with low dose botulinum toxin injection. *J Med Assoc Thai*. 2004 Oct;87(10):1205–11.